Evidence map›Paper›PMID 33103845›Full record

ArticleThoracic cancer2020

Myositis induced by durvalumab in a patient with non-small cell lung cancer: A case report.

Miyuki Kobayashi, Masafumi Saiki, Chisa Omori, Shuichiro Ide, Kazuki Masuda, Yusuke Sogami, Takanori Hata, Hiroshi Ishihara

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Miyuki KobayashiThe Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.ORCID 0000-0002-3264-2863
Masafumi SaikiThe Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
Chisa OmoriThe Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
Shuichiro IdeThe Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
Kazuki MasudaThe Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
Yusuke SogamiThe Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
Takanori HataThe Department of Neurology, University of Yamanashi, Faculty of Medicine, Chuo, Japan.
Hiroshi IshiharaThe Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
University of Yamanashi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibition is associated with a broad spectrum of immune toxicities referred to as immune-related adverse events (irAEs). Myositis is known to be a potentially fatal irAE. Here, we report a case of immune-related myositis after the administration of durvalumab. A 60-year-old man with stage IIIA lung adenocarcinoma was treated with durvalumab after concurrent chemoradiation therapy. After the third dose of durvalumab, his serum CK level was elevated, and soon thereafter myalgia of the proximal muscles and blepharoptosis were observed. We diagnosed immune-related myositis based on the results of pathological examination and initiated systemic corticosteroid therapy. His symptoms then improved and the serum CK level immediately dropped to within a normal range. Clinicians should be aware of possible myositis during the early phase of durvalumab therapy.

Indexed as

Antibodies, MonoclonalCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMaleMiddle AgedMyositisAntibodies, MonoclonaldurvalumabDurvalumabimmune-related adverse eventsmyositisnon-small cell lung cancer

Identifiers

PMID33103845
PMCPMC7705624
OpenAlexW3093595493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.